These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 1995956)

  • 21. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses.
    Murphy BR; Olmsted RA; Collins PL; Chanock RM; Prince GA
    J Virol; 1988 Oct; 62(10):3907-10. PubMed ID: 3047432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine.
    Murphy BR; Prince GA; Walsh EE; Kim HW; Parrott RH; Hemming VG; Rodriguez WJ; Chanock RM
    J Clin Microbiol; 1986 Aug; 24(2):197-202. PubMed ID: 3755730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T-cells in respiratory syncytial virus (RSV) infection.
    Askonas BA; Openshaw P; Cannon M
    Adv Exp Med Biol; 1989; 257():9-17. PubMed ID: 2533461
    [No Abstract]   [Full Text] [Related]  

  • 25. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G.
    Openshaw PJ; Clarke SL; Record FM
    Int Immunol; 1992 Apr; 4(4):493-500. PubMed ID: 1591217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge.
    Stott EJ; Ball LA; Young KK; Furze J; Wertz GW
    J Virol; 1986 Nov; 60(2):607-13. PubMed ID: 3773052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
    Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge.
    Mader D; Huang Y; Wang C; Fraser R; Issekutz AC; Stadnyk AW; Anderson R
    Vaccine; 2000 Jan; 18(11-12):1110-7. PubMed ID: 10590333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
    Murphy BR; Sotnikov A; Paradiso PR; Hildreth SW; Jenson AB; Baggs RB; Lawrence L; Zubak JJ; Chanock RM; Beeler JA
    Vaccine; 1989 Dec; 7(6):533-40. PubMed ID: 2692334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.
    Olmsted RA; Elango N; Prince GA; Murphy BR; Johnson PR; Moss B; Chanock RM; Collins PL
    Proc Natl Acad Sci U S A; 1986 Oct; 83(19):7462-6. PubMed ID: 3532115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV.
    Crowe JE; Collins PL; London WT; Chanock RM; Murphy BR
    Vaccine; 1993 Nov; 11(14):1395-404. PubMed ID: 8310760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric subgroup A respiratory syncytial virus with the glycoproteins substituted by those of subgroup B and RSV without the M2-2 gene are attenuated in African green monkeys.
    Cheng X; Zhou H; Tang RS; Munoz MG; Jin H
    Virology; 2001 Apr; 283(1):59-68. PubMed ID: 11312662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge.
    Johnson TR; Parker RA; Johnson JE; Graham BS
    J Immunol; 2003 Feb; 170(4):2037-45. PubMed ID: 12574374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice.
    Vaux-Peretz F; Chapsal JM; Meignier B
    Vaccine; 1992; 10(2):113-8. PubMed ID: 1539464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virus.
    Olmsted RA; Buller RM; Collins PL; London WT; Beeler JA; Prince GA; Chanock RM; Murphy BR
    Vaccine; 1988 Dec; 6(6):519-24. PubMed ID: 3072795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.
    Kahn JS; Roberts A; Weibel C; Buonocore L; Rose JK
    J Virol; 2001 Nov; 75(22):11079-87. PubMed ID: 11602747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection.
    Srikiatkhachorn A; Braciale TJ
    J Exp Med; 1997 Aug; 186(3):421-32. PubMed ID: 9236194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-4 diminishes CD8(+) respiratory syncytial virus-specific cytotoxic T-lymphocyte activity in vivo.
    Aung S; Tang YW; Graham BS
    J Virol; 1999 Nov; 73(11):8944-9. PubMed ID: 10515999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challenge.
    Bembridge GP; Lopez JA; Bustos R; Melero JA; Cook R; Mason H; Taylor G
    J Virol; 1999 Dec; 73(12):10086-94. PubMed ID: 10559323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.